FDA Approves Crysvita for Treatment of Tumor-Induced Osteomalacia (TIO)
Date: June 24, 2020
The U.S. Food and Drug Administration (FDA) approved Crysvita (burosumab) for treatment of hypophosphatemia in tumor-induced osteomalacia (TIO), a rare disease caused by slow-growing tumors that produce excess levels of FGF23 . Crysvita, developed by Ultragenyx, is the first FDA-approved non-surgical treatment option for those with TIO, where in approximately half the cases, surgical removal of the tumors is not possible.
For more information, please click here